Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Cirtuvivint

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biosplice Initiates Phase 1 Trial For Cirtuvivint And Olaparib
    Biosplice Initiates Phase 1 Trial For Cirtuvivint And Olaparib

    22 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/22/3209045/0/en/Biosplice-Therapeutics-Announces-First-Patient-Dosed-in-Investigator-Initiated-Phase-1-Clinical-Trial-of-Cirtuvivint-and-Olaparib-in-BRCA-HRD-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    22 Dec 2025
    Share Share
    1st Patient Dose in Trial of Biosplice's Cirtuvivint for Leukemia
    1st Patient Dose in Trial of Biosplice's Cirtuvivint for Leukemia

    09 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/09/3146697/0/en/Biosplice-Therapeutics-Announces-First-Patient-Dosed-in-NCI-Sponsored-Clinical-Trial-of-Cirtuvivint-in-Acute-Myeloid-Leukemia-and-Myelodysplastic-Syndromes.html

    GLOBENEWSWIRE
    09 Sep 2025
    Share Share
    Biosplice: First Patient Dosed in Phase 2 Trial of Cirtuvivint
    Biosplice: First Patient Dosed in Phase 2 Trial of Cirtuvivint

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072165/0/en/Biosplice-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-Cirtuvivint-for-Advanced-Soft-Tissue-Sarcomas.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.